

## Supplementary Material

### **A scoping review of remote group-based psychological interventions for people after transient ischemic attack and stroke**

*Jade Kettlewell<sup>A,\*</sup>, Eirini Kontou<sup>B</sup>, Abigail R. Lee<sup>B</sup>, Shirley Thomas<sup>C</sup>, Naomi Thorpe<sup>D</sup> and Dana Wong<sup>E</sup>*

<sup>A</sup>Centre for Academic Primary Care, University of Nottingham, UK

<sup>B</sup>Mental Health and Clinical Neurosciences, Institute of Mental Health, University of Nottingham, UK

<sup>C</sup>Injury, Recovery and Inflammation Science, School of Medicine, University of Nottingham, UK

<sup>D</sup>Library and Knowledge Services, Nottinghamshire Healthcare NHS Foundation Trust, X

<sup>E</sup>Department of Psychology, Counselling & Therapy, La Trobe University, Australia

\*Correspondence to: Email: [Jade.kettlewell@nottingham.ac.uk](mailto:Jade.kettlewell@nottingham.ac.uk)

## Supplementary File

### Supplementary File 1: Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>TITLE</b>			
Title	1	Identify the report as a scoping review.	Title page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	Abstract Page 1
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	Pages 2-4
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	Pages 4-5
<b>METHODS</b>			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	Not applicable.
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	Pages 5-6
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	Page 5
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Supplementary File 2
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	Page 6
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	Page 6
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Page 5

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	Not applicable.
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	Page 6
<b>RESULTS</b>			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Pages 6-7 Figure 1
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Pages 7-11
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable.
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Pages 7-11
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Pages 7-11 Tables 1-3
<b>DISCUSSION</b>			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	Pages 11-14
Limitations	20	Discuss the limitations of the scoping review process.	Pages 13-14
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Page 14
<b>FUNDING</b>			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Page 15

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850).

## Supplementary File 2: Search strategy

Strategy was translated to other databases.

**Platform and database:** Ovid MEDLINE® ALL <1946 to June 22, 2023>

**Date searched:** 22-06-2023

#	Search term(s)	Result(s)
1	exp Psychotherapy, Group/	27794
2	(group adj2 (training or intervention* or therap* or work* or initiative* or program* or treatment*)).tw,kw,kf.	192764
3	(Psychoeducation* or psycho-education*).tw,kw,kf.	8572
4	exp Psychotherapy/ or exp Cognitive Behavioral Therapy/ or exp Dialectical Behavior Therapy/ or exp Mindfulness/	218381
5	((acceptance* or compassion or schema) adj3 therap*).tw,kw,kf.	3168
6	(behavio* adj1 activat*).tw,kw,kf.	3011
7	((integrative or famil* or group or interpersonal or mentalisation* or psychoanalytic or "solution focused") adj1 therap*).tw,kw,kf.	22476
8	(narrative adj1 (therap* or practice*)).tw,kw,kf.	364
9	(dialectic* or DBT or mindfulness* or MBCT or MBSR or "activity schedul*" or "motivational interview*" or "eye movement desensiti?ation" or EMDR or "exposure and response prevention").tw,kw,kf.	26375
10	("cognitive behavio?r* therap*" or "cognitive behavio?r* psychotherap*" or CBT or "cognitive therap*" or "behavio?r modification").tw,kw,kf.	33538
11	(psychotherap* or psycho-therap* or "psychodynamic therap*" or "psychoanalytic therap*").tw,kw,kf.	55200
12	(psychological adj1 (therap* or treatment* or intervention*)).tw,kw,kf.	15890
13	or/1-12	454129
14	cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp cerebral small vessel diseases/ or exp intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or stroke, lacunar/	411411
15	(stroke* or poststroke or apoplex* or "cerebral vasc*" or "brain vasc*" or cerebrovasc* or CVA* or SAH).tw,kw,kf.	394313
16	((brain* or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or "middle cerebral artery" or MCA* or "anterior circulation" or "posterior circulation" or "basilar artery" or "vertebral artery") adj5 (isch?emi*	144074

	or infarct* or thrombo* or emboli* or occlus* or hypoxi*).tw,kw,kf.	
17	((brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or "basal gangli* posterior fossa" or hemispher* or subarachnoid) adj5 (h?emorrhag* or h?ematoma* or bleed*).tw,kw,kf.	95962
18	(hemipleg* or hemipar* or paresis or paraparesis or paretic).tw,kw,kf.	47522
19	("transient isch?emic attack" or "transient brainstem isch?emia" or "transient cerebral isch?emia" or TIA).tw,kw,kf.	19769
20	or/14-19	692548
21	13 and 20	10081
22	exp Telemedicine/ or Videoconferencing/ or Therapy, Computer-Assisted/	52189
23	((remote* or digital or electronic or web) adj2 (deliver* or training or consultation* or care or rehab*).tw,kw,kf.	11915
24	((tele or mobile or video) adj (application* or apps* or health or medicine or diagnosis or consultation or conference or rehab*).tw,kw,kf.	17004
25	(telemedicin* or telehealth or telediagnosis or teleconsult* or videoconferenc* or telerehab* or videophone* or teleconferenc* or telepsychiatry or teletherap*).tw,kw,kf.	41965
26	(mhealth or m-health or ehealth or e-health or emedicine or e-medicine or etherap* or e-therap*).tw,kw,kf.	20299
27	("non face-to-face" or Zoom or "MS Teams" or "Microsoft Teams" or Skype or FaceTime or "video call" or "virtual visit").tw,kw,kf.	5485
28	or/22-27	103892
29	21 and 28	233